Loading
Strata Critical Medical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Dec 2025.
Strata Critical Medical, Inc.: what insiders have been doing
Strata Critical Medical, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 11 insiders have disclosed 64 filings since 18 October 2025.
The record shows 2 purchases on the open market worth €84k, made by 2 insiders, against 7 sales worth €436k by 2 insiders. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 senior executive and 1 chief executive. Cohen Amir filed the largest sale, €206k, on 26 May 2026, which represents 0.038% of the company's market value.
Compared with its exchange (5,458 companies, median 22 filings), a count of 64 filings is above the norm. Since 2021, the database holds 6 purchases and 78 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 197.1 m USD and net income at 41.3 m USD.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 312 days ago, on 10 December 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
283
Thresholds
n/a
Buy Volume
€346,326
6 ops. · all time
Sell Volume
€12M
78 ops. · all time
Who traded when
BuySaleAmir Cohen5 sales
William A. Heyburn1 buy4 sales
Melissa M. Tomkiel4 sales
Reginald Love4 sales
Andrew Lauck1 buy
Robert S. Wiesenthal1 sale
Since the insiders bought
- -13.7%Entry US$5.26 · Close 16 Oct 2026 US$4.54
- +3.7%Entry US$4.38 · Close at T+90 US$4.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,758 of 24,148 companies
47.5
score / 100
Value51
Quality45
FCF yld-16%
Earn yld11%
EV/EBITDA·
ROE-9.2%
Gross mgn21%
Net mgn21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.28
Analyst consensus
4 analysts1.00/5
US$8.00Target US$9.56(+123%)US$12.75
Income statement
RevenueUS$197.1M
Gross profitUS$41.1M21% margin
EBITDA-US$14.2M-7% margin
Net incomeUS$41.3M15.7% margin
Valuation
P/Book1.4x
Beta2.43
Balance sheet & cash
Market capUS$378.6M
Total debtUS$3.3M
Free Cash Flow-US$59.9M
Debt / Equity2%
Profitability & ownership
ROE-9.2%
ROA-1.9%
% insiders14.3%
% institutions71.7%
Last declaration on 2 October 2026
Declarations283 total
100,000 shares@ US$5.170.12% mcap100.0% of flowClass ASEC144:0001969223-26-001051
98,356 shares@ US$5.270.11% mcap14.3% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-063576:1
177,858 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-063577:0
90,797 shares@ US$5.270.10% mcap12.8% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-063577:1
177,858 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-063576:0
4,645 shares@ US$5.310.0051% mcap2.9% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-061364:0
31,671 shares@ US$5.310.035% mcap4.5% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-061362:0
29,730 shares@ US$5.310.032% mcap4.1% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-061363:0
5,711 shares@ US$5.310.0062% mcap10.4% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-061368:0
5,697 shares@ US$5.310.0062% mcap100.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-061370:0
5,091 shares@ US$5.750.0061% mcap23.5% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-056841:0
41,786 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051809:0
27,420 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051809:1
44,438 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051826:0
181,071 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051814:0
30,913 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051822:0
208,929 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051811:0
206,953 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051811:1
50,234 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051819:0
179,160 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051814:1
35,260 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051817:0
37,675 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051824:0
57,172 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-051816:0
34,015 shares@ US$5.090.036% mcap20.6% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-051809:2
199,209 shares@ US$5.090.21% mcap27.6% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-051814:2
25 of 283 declarations
About Strata Critical Medical, Inc.
Strata Critical Medical, Inc. (NASDAQ: SRTA) is a United States-based, New York-headquartered company focused on time-critical logistics and medical services for the U.S. healthcare market. The company, formerly known as Blade Air Mobility, Inc., underwent a major strategic reset in 2025 after divesting its legacy passenger transportation business. Following that transaction, Strata emerged as a more focused, contract-driven “pure play” medical logistics and clinical services platform, with a business model that is less exposed to consumer travel demand and more anchored to healthcare infrastructure.
Strata’s core offering is built around integrated solutions for transplant hospitals and organ procurement organizations. The company provides an end-to-end “one call” solution that can include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion, preservation services, and related coordination support. These capabilities are delivered primarily through the Trinity Medical Solutions and Keystone Perfusion Services brands. In addition, Strata offers perfusion staffing and equipment solutions for cardiovascular surgery centers, broadening its addressable market beyond transplant-related procedures.
Read moreShow less
From a competitive standpoint, Strata operates in a specialized niche, but one with favorable structural dynamics. Demand is supported by the persistent shortage of donor organs, the operational complexity of transplant logistics, and the need to reduce time-sensitive delays across the care pathway. The company’s main differentiator is its integrated service model, which combines transportation, clinical coordination, and procedure execution within a single platform. Management has described Strata as operating one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations in the United States, which suggests a meaningful network position in a highly specialized segment.
Geographically, the business is primarily domestic and centered on the United States, where Strata also maintains its principal executive offices in New York. The company is not positioned as a broad international operator; instead, its strategy appears focused on deepening its U.S. footprint and expanding within adjacent medical-critical workflows.
Recent corporate milestones have been important for equity investors. In August 2025, Strata completed the sale of its Passenger business to Joby Aviation, formally closed the strategic transition, and began trading under the new ticker SRTA on NASDAQ. In September 2025, the company completed the acquisition of Keystone Perfusion Services, strengthening its capabilities in organ recovery, normothermic regional perfusion, and perfusion-related medical services. More recently, the company reported strong 2025 operating momentum in its 2026 disclosures, including revenue growth and improved guidance, which points to a more streamlined business profile and a clearer earnings narrative centered on critical healthcare services.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
